Cogent Biosciences, Inc. (COGT)
After hours:
| Previous close | 7.76 |
| Open | 7.75 |
| Bid | 7.61 x 400 |
| Ask | 7.64 x 200 |
| Day's range | 7.43 - 7.83 |
| 52-week range | 3.67 - 13.50 |
| Volume | |
| Avg. volume | 2,096,814 |
| Market cap | 726.662M |
| Beta (5Y monthly) | -0.08 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.42 |
| Earnings date | 06 Aug 2024 - 12 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 16.70 |
GlobeNewswireCogent Biosciences Reports First Quarter 2024 Financial Results
SUMMIT, PEAK and APEX registration-directed clinical trial enrollment remains on track; topline results expected from all three studies in 2025 Ended 1Q 2024 with $435.7 million in cash, sufficient to fund operations into 2027 WALTHAM, Mass. and BOULDER, Colo., May 07, 2024 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today provided a business update and announced financial results
- GlobeNewswire
Cogent Biosciences Presents Data Highlighting Potential Best-in-Class Potency and Selectivity of Novel, EGFR Sparing, CNS-Penetrant ErbB2 Inhibitor
IND-enabling studies expected to begin mid-2024WALTHAM, Mass. and BOULDER, Colo., April 09, 2024 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced new preclinical data from the Company’s potent, selective, CNS-penetrant ErbB2 inhibitor program. The data are being presented in a poster session at the American Association for Cancer Research (AACR) 2024 Annual Meeting taki
- GuruFocus.com
COGT Reports Full Year 2023 Financial Results and Business Highlights
Bezuclastinib Trials Progress as Cogent Biosciences Inc. Strengthens Cash Position
